此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors

2026年7月19日 更新者:Kangabio AUSTRALIA LTD PTY

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Single-Agent KGX105 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a first-in-human, open-label, multicenter, Phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and preliminary antitumor activity of single-agent KGX105 in participants with locally advanced or metastatic solid tumors. The study consists of two parts: Phase 1a dose escalation and Phase 1b dose expansion.

研究概览

地位

尚未招聘

研究类型

介入性

注册 (估计的)

85

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国、510060
        • Sun Yat-sen University Cancer Center
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Male or female participants with age ≥18 years, at the time of signing the informed consent.
  2. Dose Escalation Phase (Phase Ia):

    Participants with histologically or cytologically confirmed locally advanced or metastatic malignant solid tumors meeting any of the following conditions:

    • Have received prior standard systemic anti-tumor therapy recommended by current guidelines for their tumor type and stage, and experienced disease progression or unacceptable toxicity during or after treatment;
    • Have no effective standard therapy available at present;
    • Meet any of the following conditions rendering standard therapy unsuitable:

      • Presence of known standard contraindications to standard therapy for their tumor type; •② Prior discontinuation of standard therapy due to intolerable toxicity; •③ Explicit refusal to receive available standard therapy.
    • Priority: Non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), pancreatic cancer, and other EGFR-positive* solid tumors such as gastroesophageal junction adenocarcinoma, gastric cancer, and esophageal squamous cell carcinoma.
  3. Dose Expansion Phase (Phase Ib):

    • Cohort 1 (EGFR-positiveNSCLC):*
    • Participants with driver gene-positive NSCLC must have received approved targeted therapy for the identified driver gene unless contraindicated; treatment discontinuation must be due to disease progression or intolerable toxicity. Driver genes primarily include: EGFR exon 19 deletion, L858R mutation, or exon 20 insertion mutation.
    • Participants with EGFR protein overexpression or gene amplification in driver gene-negative NSCLC must have received platinum-based chemotherapy and anti-PD-(L)1 antibody therapy (concurrent or sequential), unless contraindicated; treatment discontinuation must be due to disease progression or intolerable toxicity.
    • Cohort 2 (EGFR-positiveHNSCC, NPC):*
    • HNSCC participants must have received immune checkpoint inhibitors and/or platinum-based chemotherapy (with or without cetuximab).
    • NPC participants must have received platinum-based chemotherapy, with or without anti-PD-(L)1 antibodies.
    • Cohort 3 (Other EGFR-positivesolid tumors):*
    • Pancreatic cancer, gastric cancer, gastroesophageal junction adenocarcinoma, and esophageal squamous cell carcinoma that have progressed after at least one line of standard therapy.
    • Definition of EGFR-positivein this study:* Includes any of the following: EGFR protein overexpression (EGFR IHC staining intensity ≥1+), EGFR gene mutation, or EGFR gene amplification (by NGS).
  4. According to RECIST 1.1, there must be at least one measurable lesion (tumor lesions located in a previously irradiated area or other sites of locoregional therapy generally are not considered measurable unless they have demonstrated clear progression or have persisted for three months after radiation therapy).

    Note: Metastatic brain lesions are not considered as target lesions.

  5. ECOG 0-1.
  6. Life expectancy of ≥3 months, in the opinion of the investigator.
  7. Adequate organ function as determined by medical evaluation including:

    • Adequate hematologic status, defined as: absolute neutrophil count (ANC) ≥1.5×109/L, hemoglobin ≥90 g/L, platelets ≥100×109/L. Platelet transfusions are not permitted within 7 days, red blood cell transfusions are not permitted within 14 days, hematopoietic growth factors are not permitted within 7 days (14 days for PEGylated G-CSF or erythropoietin) prior to obtaining these laboratory values.
    • Adequate hepatic function, defined as: serum TBIL ≤1.5×ULN (in participants with known Gilbert's syndrome, TBIL ≤3×ULN with direct bilirubin ≤1.5×ULN), serum ALT or AST ≤2.5×ULN (or ≤5.0×ULN for documented liver metastasis).
    • Adequate renal function, defined as: creatinine clearance ≥60 mL/min (measured or calculated by Cockcroft and Gault equation).
    • Adequate coagulation profile, defined as (including if receiving anticoagulation therapy): prothrombin time (PT) <1.5×ULN, activated partial thromboplastin time (APTT) <1.5×ULN. If the participant is on anticoagulation therapy, must be on a stable dose of anticoagulant for ≥1 month prior to study treatment.
  8. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to treatment.
  9. Women of childbearing potential or male partners of women of childbearing potential must agree to use highly effective contraception throughout the treatment period and for 4 months after the last dose.
  10. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this study.

Exclusion Criteria:

  1. Diagnosis of another malignancy within 5 years prior to the first dose, except for:

    • Curatively resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ;
    • Localized prostate cancer or papillary thyroid carcinoma post curative resection.
  2. Presence of leptomeningeal metastasis, spinal cord compression, symptomatic brain metastases, or brain metastases requiring steroids/antiepileptic drugs or showing radiographic progression within 4 weeks prior to enrollment.

    •Exception:Asymptomatic brain metastases, or those stable for >4 weeks post-treatment without requiring steroids/antiepileptics, with a single lesion ≤1.5 cm and total number of lesions ≤5, are allowed.

  3. History of allogeneic organ transplantation, allogeneic peripheral hematopoietic stem cell transplantation, or bone marrow transplantation.
  4. Pregnant or breastfeeding women, or individuals planning to donate sperm/eggs during the study period (from ICF signing to 4 months after the last dose).

    •Note:Breastfeeding women may be enrolled if they agree to stop breastfeeding prior to dosing and have no intention of resuming.

  5. Any severe or uncontrolled systemic disease, including:

    1. Active bleeding or known bleeding diathesis;
    2. Cardiac dysfunction or clinically significant cardiovascular disease, including any of the following:

      •Uncontrolled cardiac disease, such as congestive heart failure requiring treatment (NYHA > Class II);

      •Uncontrolled hypertension (resting BP ≥160/100 mmHg);

      •Poorly controlled arrhythmias;

      •ECG with QTcF >470 ms (female) or >450 ms (male) (QTcF = QT/RR¹/³), or congenital long QT syndrome;

      •Echocardiogram: Left Ventricular Ejection Fraction (LVEF) ≤50%;

      •Acute myocardial infarction or unstable angina within 6 months prior to study entry;

    3. Uncontrolled diabetes mellitus or poor compliance with hypoglycemic agents;
    4. Other chronic diseases that, in the investigator's opinion, may compromise participant safety or preclude completion of the study.
  6. Active infections:

    1. Known Human Immunodeficiency Virus (HIV) infection, Treponema pallidum (TP) infection;
    2. Active Hepatitis B [i.e., HBsAg positive and HBV DNA >1000 copies/mL (or 200 IU/mL), or HBV DNA above the lower limit of detection (if the LLOQ at the site is >200 IU/mL)];
    3. Hepatitis C Virus (HCV) infection (i.e., HCV antibody positive and HCV-RNA positive);
    4. Other active infections requiring systemic therapy within 2 weeks prior to the first dose.
  7. Inadequate recovery from any prior surgery, or major organ surgery (excluding core needle biopsy or vascular intervention) within 4 weeks prior to study drug administration.
  8. Receipt of any of the following treatments:

    A. Prior treatment with T-cell engager drugs containing CD3 antibodies. B. Within the respective washout periods or 5 half-lives (whichever is shorter) prior to the first dose: Chemotherapy, biotherapy, or immunotherapy within 4 weeks; targeted therapy, radiotherapy, endocrine therapy, or oral fluoropyrimidines within 2 weeks; anti-tumor traditional Chinese medicine within 1 week; nitrosoureas or mitomycin C within 6 weeks.

    C. Live or attenuated live vaccines within 4 weeks prior to the first dose (inactivated vaccines are allowed).

    D. Diagnosis of immunodeficiency, receipt of immunosuppressive therapy, or chronic systemic/enteral steroid therapy (>10 mg/day prednisone or equivalent).

    E. Interstitial pneumonia, pulmonary fibrosis, pneumoconiosis, drug-induced pneumonitis, radiation pneumonitis requiring steroids or other treatment, or a history of severe pulmonary function impairment/restrictive lung disease.

  9. Adverse events from prior anti-tumor therapy have not resolved to CTCAE v6.0 Grade ≤1 (except for alopecia, peripheral neuropathy, ototoxicity, or stable endocrinopathies managed with hormone replacement).
  10. Known hypersensitivity to the active ingredient or any excipients of the investigational product.
  11. History of immunotherapy-related adverse events ≥ Grade 3 or leading to treatment discontinuation.
  12. History of active autoimmune disease likely to recur (e.g., SLE, RA, Crohn's, ulcerative colitis, vasculitis), except:

    • Clinically stable autoimmune thyroid disease;
    • Use of inhaled or topical corticosteroids (ocular, intra-articular, nasal) with daily dose equivalent to ≤10 mg prednisone;
    • Short-term corticosteroid use (≤7 days) for prophylaxis (e.g., contrast allergy);
    • Replacement therapy (e.g., thyroxine for hypothyroidism, insulin for diabetes, physiological steroid replacement for adrenal/pituitary insufficiency).
  13. Presence of symptomatic pleural, peritoneal, or pericardial effusion requiring paracentesis/drainage at screening.

    •(Exclusion applies if drainage/intracavitary therapy was performed more than once [i.e., ≥2 times] for any cavity within 14 days prior to the first dose).

  14. History of active tuberculosis within 1 year prior to enrollment.
  15. History of thrombotic events (arterial or venous) within 6 months prior to screening, including cerebrovascular accidents (e.g., hemorrhage, infarction), deep vein thrombosis (DVT), and pulmonary embolism (PE).

    • Exception:Catheter-related thrombosis due to PICC or port placement may be allowed if deemed stable, asymptomatic, or adequately treated with no bleeding risk by the investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:KGX105 monotherapy-Dose level 1
KGX105 is an investigational EGFR×CD3 TCE prodrug engineered with masked binding domains to reduce on-target, off-tumor toxicity and systemic activation. It is selectively activated in the tumor microenvironment (TME) to target EGFR-positive tumors. An integrated albumin-binding domain prolongs systemic half-life, optimizing drug exposure and efficacy.KGX105 injection is a sterile, white or slightly yellow lyophilized powder, supplied at 10.0 mg/vial for single use.
实验性的:KGX105 monotherapy-Dose level 2
KGX105 is an investigational EGFR×CD3 TCE prodrug engineered with masked binding domains to reduce on-target, off-tumor toxicity and systemic activation. It is selectively activated in the tumor microenvironment (TME) to target EGFR-positive tumors. An integrated albumin-binding domain prolongs systemic half-life, optimizing drug exposure and efficacy.KGX105 injection is a sterile, white or slightly yellow lyophilized powder, supplied at 10.0 mg/vial for single use.
实验性的:KGX105 monotherapy-Dose level 3
KGX105 is an investigational EGFR×CD3 TCE prodrug engineered with masked binding domains to reduce on-target, off-tumor toxicity and systemic activation. It is selectively activated in the tumor microenvironment (TME) to target EGFR-positive tumors. An integrated albumin-binding domain prolongs systemic half-life, optimizing drug exposure and efficacy.KGX105 injection is a sterile, white or slightly yellow lyophilized powder, supplied at 10.0 mg/vial for single use.
实验性的:KGX105 monotherapy-Dose level 4
KGX105 is an investigational EGFR×CD3 TCE prodrug engineered with masked binding domains to reduce on-target, off-tumor toxicity and systemic activation. It is selectively activated in the tumor microenvironment (TME) to target EGFR-positive tumors. An integrated albumin-binding domain prolongs systemic half-life, optimizing drug exposure and efficacy.KGX105 injection is a sterile, white or slightly yellow lyophilized powder, supplied at 10.0 mg/vial for single use.
实验性的:KGX105 monotherapy-Dose level 5
KGX105 is an investigational EGFR×CD3 TCE prodrug engineered with masked binding domains to reduce on-target, off-tumor toxicity and systemic activation. It is selectively activated in the tumor microenvironment (TME) to target EGFR-positive tumors. An integrated albumin-binding domain prolongs systemic half-life, optimizing drug exposure and efficacy.KGX105 injection is a sterile, white or slightly yellow lyophilized powder, supplied at 10.0 mg/vial for single use.
实验性的:KGX105 monotherapy-Dose level 6
KGX105 is an investigational EGFR×CD3 TCE prodrug engineered with masked binding domains to reduce on-target, off-tumor toxicity and systemic activation. It is selectively activated in the tumor microenvironment (TME) to target EGFR-positive tumors. An integrated albumin-binding domain prolongs systemic half-life, optimizing drug exposure and efficacy.KGX105 injection is a sterile, white or slightly yellow lyophilized powder, supplied at 10.0 mg/vial for single use.
实验性的:KGX105 monotherapy-Dose level 7
KGX105 is an investigational EGFR×CD3 TCE prodrug engineered with masked binding domains to reduce on-target, off-tumor toxicity and systemic activation. It is selectively activated in the tumor microenvironment (TME) to target EGFR-positive tumors. An integrated albumin-binding domain prolongs systemic half-life, optimizing drug exposure and efficacy.KGX105 injection is a sterile, white or slightly yellow lyophilized powder, supplied at 10.0 mg/vial for single use.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Numbers of participants with adverse events(Phase Ia)
大体时间:From baseline to 30 days after the last dose administration.
AE will be collected to assess participants' safety after KGX105 monotherapy
From baseline to 30 days after the last dose administration.
Incidence of Dose-Limiting Toxicities (DLTs) during the DLT observation period.(Phase Ia)
大体时间:From Day1 after the first priming dose of KGX105 until 21 days post the first target dose of KGX105
DLT will be observed from start of the first priming dose of KGX105 until 21 days post the first target dose of KGX105
From Day1 after the first priming dose of KGX105 until 21 days post the first target dose of KGX105
Number of participants with changes of clinical lab abnormalities(Phase Ia)
大体时间:From screening until 90 days post the last dose administration
Any changes in values of the clinical chemistry, hematology, coagulation and urinalysis will be evaluated
From screening until 90 days post the last dose administration
The maximum tolerated dose of KGX105 monotherapy(Phase Ia)
大体时间:From Day 1 post the first dosing until 21 days post the the first target dosing
From Day 1 post the first dosing until 21 days post the the first target dosing
Objective Response Rate (ORR) of KGX105 monotherapy (Phase Ib)
大体时间:until progression or death,whichever came first, assessed up to 2 years
The ratio of participants assessed with complete response (CR) or partial response (PR) as a best overall response.
until progression or death,whichever came first, assessed up to 2 years

次要结果测量

结果测量
措施说明
大体时间
Maximum observed concentration (Cmax) of KGX105 following single and multiple doses
大体时间:From pre-dose of the first dose of KGX105 treatment until Day 1 of the last dose.
Pharmacokinetic (PK) parameters
From pre-dose of the first dose of KGX105 treatment until Day 1 of the last dose.
Objective Response Rate (ORR) of KGX105 monotherapy (Phase Ia)
大体时间:From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.
The ratio of participants assessed with complete response (CR) or partial response (PR) as a best overall response.
From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.
Disease Control Rate (DCR) of KGX105 monotherapy
大体时间:From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.
The ratio of subjects assessed with CR or PR or stable disease (SD) as a best overall response.
From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.
Duration of Response(DoR)of KGX105 monotherapy
大体时间:From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.
DoR defined as the time from first documented evidence of CR or PR until disease progression or death.
From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.
Progression-Free Survival (PFS) of KGX105 monotherapy
大体时间:From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.
PFS defined as the time from first dose to radiographic progression or death due to any cause
From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.
Overall Survival (OS) of KGX105 monotherapy
大体时间:From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.
OS defined as the time from first dose to death due to any cause
From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.
Immunogenicity- Anti-drug antibody (ADA)、Neutralizing Antibodies(Nab)
大体时间:Samples will be collected to assess the immunogeniccity after each KGX105 treatment.
Samples will be collected to assess the immunogeniccity after each KGX105 treatment.
Samples will be collected to assess the immunogeniccity after each KGX105 treatment.
Numbers of participants with adverse events(Phase Ib)
大体时间:From baseline to 30 days after the last dose administration
AE will be collected to assess participants' safety after KGX105 monotherapy
From baseline to 30 days after the last dose administration
Number of participants with changes of clinical lab abnormalities(Phase Ib)
大体时间:From screening until 90 days post the last dose administration
Any changes in values of the clinical chemistry, hematology, coagulation and urinalysis will be evaluated
From screening until 90 days post the last dose administration
Phase 2 dose (RP2D) of KGX105 monotherapy (Phase Ib)
大体时间:From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.
From Day 1 after the first dose of KGX105 till survival follow-up every 90 days post the last treatment.
Time to Cmax (Tmax)of KGX105 following multiple doses
大体时间:From pre-dose of the first dose of KGX105 treatment until Day 1 of the last dose
Pharmacokinetic (PK) parameters
From pre-dose of the first dose of KGX105 treatment until Day 1 of the last dose
Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC₀-ₜ), AUC from time zero extrapolated to infinity (AUC₀-∞)
大体时间:From pre-dose of the first dose of KGX105 treatment until Day 1 of the last dose
Pharmacokinetic (PK) parameters
From pre-dose of the first dose of KGX105 treatment until Day 1 of the last dose
Elimination half-life (t₁/₂) of KGX105 following multiple doses
大体时间:From pre-dose of the first dose of KGX105 treatment until Day 1 of the last dose
Pharmacokinetic (PK) parameters
From pre-dose of the first dose of KGX105 treatment until Day 1 of the last dose

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:li Zhang、Sun Yat-sen University Cancer Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月1日

初级完成 (估计的)

2028年9月1日

研究完成 (估计的)

2028年11月1日

研究注册日期

首次提交

2026年7月2日

首先提交符合 QC 标准的

2026年7月10日

首次发布 (实际的)

2026年7月14日

研究记录更新

最后更新发布 (实际的)

2026年7月21日

上次提交的符合 QC 标准的更新

2026年7月19日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • KGX105ST102

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅